Based on our finding that depletion of mevalonate-derived metabolites inhibits adipocyte differentiation, we hypothesize that trans, trans-farnesol (farnesol), a mevalonate-derived sesquiterpene, induces adipocyte differentiation. Farnesol dosedependently (25-75 lmol/L) increased intracellular triglyceride content of murine 3T3-F442A pre-adipocytes measured by AdipoRed TM Assay and Oil Red-O staining. Concomitantly, farnesol dose-dependently increased glucose uptake and glucose transport protein 4 (GLUT4) expression without affecting cell viability. Furthermore, quantitative real-time polymerase chain reaction and Western blot showed that farnesol increased the mRNA and protein levels of peroxisome proliferator-activated receptor g (PPARg), a key regulator of adipocyte differentiation, and the mRNA levels of PPARg-regulated fatty acid-binding protein 4 and adiponectin; in contrast, farnesol downregulated Pref-1 gene, a marker of pre-adipocytes. GW9662 (10 mmol/L), an antagonist of PPARg, reversed the effects of farnesol on cellular lipid content, suggesting that PPARg signaling pathway may mediate the farnesol effect. Farnesol (25-75 lmol/L) did not affect the mRNA level of 3-hydroxy-3-methylglutaryl coenzyme A reductase, the rate-limiting enzyme in the mevalonate pathway. Farnesol may be the mevalonate-derived inducer of adipocyte differentiation and potentially an insulin sensitizer via activation of PPARg and upregulation of glucose uptake.
Introduction
Adipocyte differentiation is a well-coordinated multi-step process involving several genes. 1, 2 Two transcriptional factors, peroxisome proliferator-activated receptor g (PPARg) and CCAAT/enhancer-binding protein a (C/EBPa), are known as the major regulators of adipogenesis and are located at the core of the adipogenic cascade. Sterol regulatory element-binding protein 1 (SREBP-1), another key lipogenic transcription factor that produces ligands for PPARg, is nutritionally regulated by glucose and insulin. 3 In two of the established pre-adipocyte cell lines, insulin or insulin-like growth factor 1 (IGF-1) are the main hormones required for cell differentiation. 1 Insulin induces the translocation of glucose transport protein 4 (GLUT4) vesicles from the cytoplasm to the plasma membrane by activating the phosphatidylinositol-3 kinase-protein kinase B/Akt (PI3K-PKB/Akt) pathway. 4 Consequently, increased glucose uptake provides the main source of energy for triglyceride synthesis in adipocytes. Dysregulation of adipocyte differentiation and lipogenesis is associated with pathological conditions such as obesity, type II diabetes, and lipodystrophy.
Our previous studies showed that mevalonate depletion mediated by lovastatin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase that is the rate-limiting enzyme in the mevalonate pathway, reduced the intracellular triglyceride content of murine 3T3-F442A adipocytes. Concomitantly, lovastatin downregulated the expression of Pparg, Cebpa, leptin, fatty acid-binding protein 4 (Fabp4), adiponectin (AdipoQ), and Srebp-1 genes. Supplemental mevalonate reversed the effects of lovastatin, suggesting that mevalonate or mevalonate-derived metabolites are essential for adipocyte differentiation.
The identity of the mevalonate-derived molecule that promotes adipocyte differentiation remains elusive, though studies have examined a number of mevalonatederived metabolites, including farnesol and geraniol, for their roles in adipogenesis. 5, 6 The reports that farnesol, a minor constituent of basil oil 7 shown to have hypoglycemic effect in humans 8 and rats, 9 and the farnesol metabolite farnesyl pyrophosphate (FPP) activate PPARg 6,10 prompted us to examine the impact of farnesol on the differentiation of 3T3-F442A adipocytes. The effects of farnesol on glucose uptake, PPARg, and PPARg-regulated adipogenic genes including Fabp4 and AdipoQ as well as the potential role of PI3K signaling were also examined.
Materials and methods

Chemicals
Lovastatin was a gift from Merck Research Laboratories (Rahway, NJ). Farnesol, insulin, rosiglitazone, GW9662, and LY294002 were purchased from Sigma Aldrich (St. Louis, MO). Antibodies against GLUT4 and PPARg were purchased from EMD Millipore (Billerica, MA), and those for calnexin and b-actin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Culture and Oil Red-O staining of 3T3-F442A cells
Murine 3T3-F442A cells purchased from Dr. Howard Green (Harvard Medical School) were cultured in six-well (5 Â 10 3 cells/2 mL medium/well) plates in Dulbecco's modified Eagle's medium (DMEM) adjusted by American Type Culture Collection (ATCC, Manassas, VA) to contain 4 mmol/L L-glutamine, 1.5 g/L sodium bicarbonate and 4.5 g/L glucose, supplemented with 10% bovine calf serum (Fisher Scientific Company LLC, Houston, TX), and 1% penicillin/streptomycin (GIBCO, Grand Island, NY) at 37 C in a humidified atmosphere of 10% CO 2 . Upon reaching 100% confluency, the 3T3-F442A cells were switched from the growth medium above to DMEM supplemented with 10% fetal bovine serum (FBS, Fisher Scientific Company), 10 lg/mL insulin, and 1% penicillin/streptomycin (GIBCO) and incubated for 24 h; cells were then changed to differentiation medium (DMEM with 10% FBS) supplemented with test agents. Control cells were incubated in medium containing ethyl alcohol or dimethyl sulfoxide (ATCC) (0.1%, v/v) that was used to dissolve the test agents. Where applicable, 1 mmol/L rosiglitazone (an agonist of PPARg), 10 mmol/L GW9662 (an antagonist of PPARg), and 10 mmol/L LY294002 (a PI3K inhibitor) were supplemented in the medium. Cells were continued in medium without insulin for additional six to seven-days until the approximated 70-80% cells differentiate into adipocytes with lipid droplets. Cells were rinsed with phosphate-buffered saline (PBS) twice and fixed in 1 mL of 10% formalin per well at room temperature for 1 h. Cells were then rinsed with water and stained with 0.5 mL of 0.3% fresh Oil Red-O per well at room temperature for 30 min to visualize cellular neutral lipids. The cells were then washed with 1 mL of water per well for three times before photomicrographs of representative fields of monolayers of 3T3-F442A cells were taken with a Nikon Eclipse TS 100 microscope (Nikon Corporation, Tokyo, Japan) equipped with a Nikon Coolpix 995 digital camera (Nikon Corporation).
AdipoRed TM assay for measuring intracellular triglyceride content Seven to eight days after the induction of differentiation, lipid content was quantified using an AdipoRed TM assay kit (Lonza, Walkersville, MD) according to manufacturer's instructions. Differentiated cells were rinsed with 2 mL of PBS, and to each well 5 mL of PBS and 140 lL of AdipoRed TM reagent were added. After 10-15 min of incubation, the plates were positioned in a Tecan Infinite M200 microplate reader (Tecan Systems Inc., Salzburg, Austria), and fluorescence was measured with an excitation wavelength of 485 nm and an emission wavelength of 572 nm.
Cell viability assay
Following seven to eight days of incubation with 0-75 mmol/L, farnesol in six-well plates containing differentiation medium, detached murine 3T3-F442A adipocytes in culture medium were collected; monolayers of differentiated murine 3T3-F442A adipocytes were trypsinized and combined with floaters. The total number of cells and dead cells with trypan blue staining were counted with a hemocytometer. Viability of cells was expressed as the percentage of total cells that were excluding trypan blue staining.
Glucose uptake assay
Murine 3T3-F442A pre-adipocytes were cultured and induced to differentiate as described above. On day 4 of differentiation, the medium was changed and cells continued incubation until day 8 when an aliquot of medium was sampled along with fresh medium for the measurement of glucose concentration using a Stanbio Glucose LiquiColor kit Õ (Stanbio Laboratory, Boerne, TX). Reduction of medium volume due to evaporation during the incubation period was determined separately and compensated in calculation. The difference in glucose concentration between fresh medium and medium from day 8 was considered as cellular glucose uptake.
Quantitative real-time polymerase chain reaction
Murine 3T3-F442A cells cultured in six-well plates at 5 Â 10 3 cells/2 mL medium/well were incubated for seven to eight days until they fully differentiated. Total cellular RNA was extracted using TRIZOL reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's protocols. RNA concentration was determined using 25 A 260 nm /mg RNA, and purity of the isolated total RNA was determined spectrophotometrically using A 260 nm /A 280 nm ; a minimal ratio of 1.9 was required for further analysis. The integrity of the purified total RNA was verified by analysis of the 28S/18S ribosomal RNA (rRNA) ratio using gel electrophoresis. Samples were run on a 1.5% agarose gel (Trisacetate (TAE) buffer) at 80 volts for 90 min and visualized by Chemi Doc XRS imaging system (Bio-Rad, Hercules, CA) following the addition of 0.5 lg/ml ethidium bromide.
The mRNA expression levels of Pparg, Fabp4, AdipoQ, Pref-1, HMG CoA reductase, and GLUT4 were analyzed by reverse transcription followed by quantitative real-time polymerase chain reaction (qRT-PCR). Oligo (dT) 20 primer and SuperScript Õ III first-strand kit (Invitrogen, Grand Island, NY) were used to reverse transcribe 2 lg of total RNA in a 20 lL reaction buffer into cDNA following the manufacturer's instructions. cDNA was diluted by 25-fold with 25 lg/ml acetylated bovine serum albumin solution, and 6 lL of diluted cDNA was amplified in a 25 lL polymerase chain reaction (PCR) solution containing 250 nmol/ L of both forward and reverse primers of the gene and iQ TM SYBR Õ Green Supermix (Bio-Rad). Primers (Table 1) were designed using Vector NTI Advance version 11 software (Invitrogen). The cDNA was denatured at 95 C for 3 min followed by 40 cycles of PCR (94 C for 30 s, 60 C for 25 s, 72 C for 25 s, and 78 C for 9 s) by means of an iQ TM 5 multicolor Real-Time PCR Detection System (Bio-Rad) with Bio-Rad iQ5 Optical System Software (version 2.1). The mRNA levels of all the genes were normalized using ribosomal protein L22 (RPL22) as internal control 11 and the ÁC T method. Fold changes of gene expression were calculated by the 2 ÀÁÁCT method.
Western blot
Following seven to eight days of incubation with the test agents, 3T3-F442A adipocytes were scraped and centrifuged at 1250 r/min for 5 min at 4 C. Cell pellets were washed in ice-cold PBS. Membrane fractions of cell lysates prepared as previously reported 12 were used for GLUT4 blots, and non-membrane fractions were used for PPARg blots. Protein concentration of each sample was determined with the BCA TM Protein Assay Kit (Pierce, Rockford, IL). Samples were mixed with equal volume of buffer (62.5 mmol/L Tris-HCl, pH 6.8, 15% (w/v) SDS, 8 mol/L urea, 10% (v/v) glycerol and 100 mmol/L dithiothreitol) and 1/6 volume of the 4 Â SDS loading buffer (150 mmol/L Tris-HCl, pH 6.8, 12% (w/v) SDS, 30% glycerol, 6% b-mercaptoethanol, and bromphenol blue) and incubated at 37 C for 20 min prior to loading to a 8% SDS polyacrylamide gel.
Electrophoresis with a Mini PROTEAN Õ 3 (Bio-Rad) unit and Western blot was performed as described. 12 
Statistics
One-way analysis of variance (ANOVA) tests were performed to assess the differences between groups using Prism Õ 4.0 software (GraphPad Software Inc., San Diego, CA). Differences in means were analyzed by Dunnett's multiple comparison test unless specified otherwise. Values were mean AE SD. Levels of significance were designated as P < 0.05.
Results
We first determined the impact of farnesol on the differentiation of murine 3T3-F442A cells. Figure 1 To exclude the possible cytotoxicity of farnesol that might have led to reduced number of viable cells and hence reduced cellular triglyceride content, 3T3-F442A adipocytes, following an eight-day differentiation and concomitant incubation with 0, 25, 50, and 75 lmol/L farnesol, were harvested for total cell counts and measure of percentage of viable cells using trypan blue staining. Values for all groups were within 90-110% of the control value (0 lmol/L farnesol) with no statistically significant difference Table 1 Primer sequences (forward and reverse) and GenBank accession numbers used in the quantitative real-time polymerase chain reaction (qRT-PCR)
Gene
Accession # PRIMER sequence
Pparg: peroxisome proliferator-activated receptor g; Fabp4: fatty acid-binding protein 4; AdipoQ: adiponectin; Pref-1: pre-adipocyte factor1; HMG CoA reductase: 3-hydroxy-3-methylglutaryl coenzyme A reductase; GLUT4: glucose transport protein4; RPL22: ribosomal protein L22. observed between any groups for cell number or viability (data not shown).
We then examined whether farnesol-induced 3T3-F442A adipocyte differentiation was accompanied by changes in cellular glucose uptake. Farnesol at 50 and 75 lmol/L significantly induced glucose uptake (P < 0.001) (Figure 2(a) ). Concomitantly, glucose transporter GLUT4 mRNA level was increased by 50 (P < 0.05) and 75 (P < 0.01) lmol/L farnesol (Figure 2(b) ). As a negative control, undifferentiated (UD) 3T3-F442A pre-adipocytes (UD, Figure 2 (b)) had undetectable levels of GLUT4 mRNA. Consistent with these observations, Western blot showed farnesol-mediated induction of membrane GLUT4 protein expression. Lovastatin, an inhibitor of 3T3-F442A differentiation, 12 and rosiglitazone down-and up-regulated GLUT4 expression, respectively (Figure 2(c) ).
Our previous finding that lovastatin-mediated downregulation of PPARg expression was reversed by mevalonate supplementation 12 prompted us to examine next the effect of farnesol, a mevalonate-derived metabolite, on PPARg expression. Consistent with the aforementioned mevalonate effect, farnesol at 50 and 75 lmol/L upregulated PPARg mRNA level significantly (Figure 3(a) ), parallel to its effect on intracellular lipid content (Figure 1 ), cellular glucose uptake (Figure 2(a) ) and GLUT4 expression (Figure 2(b) and (C)). In contrast, UD 3T3-F442A cells had an extremely low level of PPARg mRNA (UD, Figure 3(a) ). Western blot confirmed farnesol-mediated regulation of PPARg (Figure 3(b) ). Consistent with their effects on GLUT4 expression (Figure 2(c) ), lovastatin and rosiglitazone had opposite effects on PPARg protein expression ( Figure 3(b) ). To examine whether PPARg upregulation mediates the pro-differentiation effect of farnesol, we incubated 3T3-F442A pre-adipocytes with blends of farnesol and GW9662, a PPARg antagonist (Figure 3(c) ). GW9662 at 10 lmol/L attenuated the upregulation of cellular lipid content induced by 50 lmol/L farnesol (P < 0.001). Though 25 lmol/L farnesol alone did not change lipid content, it attenuated the effect of 10 lmol/L GW9662.
To further confirm the effect of farnesol on PPARg and 3T3-F442A differentiation, we measured the mRNA levels of two PPARg-regulated genes, AdipoQ and Fabp4, and a pre-adipocyte-specific gene, pre-adipocyte factor 1 (Pref-1) ( Figure 4 ). Farnesol induced the mRNA expression of AdipoQ (Figure 4(a) ) and Fabp4 (Figure 4(b) ); the mRNA level of both genes stayed low in UD cells.In contrast, farnesol dose-dependently downregulated the mRNA level of Pref-1, a differentiation-inhibitory gene highly expressed in UD cells 13 (Figure 4(c) ).
It has been suggested that lovastatin-mediated mevalonate deprivation interferes with insulin signaling 14 and reduces adipocyte triglyceride content. 12 In response, we determined the effect of an inhibitor of insulin signaling on farnesol-mediated increase in adipocyte triglyceride content. Consistent with the finding shown in Figure 1 and in contrast to the effect of farnesol (50 lmol/L), PI3K inhibitor LY294002 (10 lmol/L) significantly reduced the cellular triglyceride content of cells. Farnesol had no effect in rescuing the inhibition mediated by LY294002 ( Figure 5 ).
Discussion
Our previous finding that lovastatin-mediated mevalonate deprivation inhibits adipocyte differentiation suggested the essential role of mevalonate. The observation that >10 mmol/L mevalonate was required to reverse the effect of statins 12,15 also suggested a mevalonate-derived metabolite, rather than mevalonate per se, plays a more direct role. The additional finding that mevalonate-derived nonsterols, including geraniol and with a greater potency, farnesol, attenuated statin-induced inhibition of preadipocyte differentiation 5 prompted us to evaluate the role of farnesol in 3T3-F442A adipocytes, a proven model 12 to study the role of mevalonate-deprived agents in adipogenesis.
Our present study shows that farnesol concentrationdependently induces the differentiation of 3T3-F442A adipocytes. The induction of differentiation is accompanied by upregulated uptake of glucose and expression of GLUT4, a PPARg-regulated gene. 16 Concomitantly, PPARg expression and other PPARg-regulated adipogenic genes including AdipoQ, a biomarker for insulin sensitivity, 17 and Fabp4 are also upregulated. Consistent with farnesol-mediated induction of differentiation, the Pref-1 gene, a negative regulator of adipocyte differentiation, 13 was downregulated by farnesol.
Our finding of farnesol as an adipocyte differentiationpromoting agent via PPARg upregulation, further confirmed by the attenuation of farnesol effect by the PPARg antagonist GW9662, is consistent with the observation that FPP, a downstream metabolite of mevalonate, is an endogenous PPARg agonist; 10 in that study, the effect of FPP on 3T3-L1 differentiation was also counteracted by a PPARg antagonist. The concentration of FPP (1 mmol/L)-much lower than that reported herein for farnesol-required for PPARg activation and adipocyte differentiation suggests phosphorylation of farnesol and conversion to FPP 18 as a possible mode of action for farnesol. A separate study with 3T3-L1 cells also showed that 50 mmol/L farnesol, a level comparable to those used in the present study, activated PPARg in a reporter assay; farnesol had the highest potency among several isoprenoids evaluated therein in activating PPARg-regulated FABP4 expression. 6 Farnesyl phosphate and FPP competed with rosiglitazone for PPARg binding with IC50 values for ligand displacement approximating 19 mmol/L, a value much lower than that of farnesol; the latter was nevertheless more efficacious in activating PPARg in CV-1 cells transfected with a reporter gene, 19 suggesting a possible farnesol metabolite with higher potency than those of the phosphorylated products of farnesol. In human HCT, 116 colorectal cancer cells, farnesol at 50 and 100 mmol/L increased PPARg promoter activity, an effect that mediates the growth-inhibitory activity of farnesol. 20 Literature also suggests that farnesol and FPP may promote adipocyte differentiation through protein prenylation. The expression of geranylgeranyl pyrophosphate (GGPP) synthase, an enzyme that catalyzes the conversion of FPP to GGPP, another substrate for protein prenylation, is upregulated by 20-fold in differentiating 3T3-L1 adipocytes and by 5-20-fold in adipose tissue from ob/ob mice. 21 Insulin, a strong promoter of adipocyte differentiation, stimulates the activities of farnesyl transferase 22 and geranylgeranyl transferase II 23 and the prenylation of small G proteins including Ras, 22 Rho, 24 Rab-3, and Rab-4 23 in 3T3-L1 adipocytes, whereas inhibitors of farnesyl-and geranylgeranyltransferases blunt 3T3-L1 differentiation. Insulin-mediated upregulation of the mevalonate pathway is not restricted to adipocytes because both HMG CoA synthase and HMG CoA reductase were shown to be upregulated by insulin in keratinocytes. 25 Coincidentally, the mevalonate-, FPP-and GGPPproducing HMG CoA reductase expression is upregulated in differentiating 26 and differentiated 27 3T3-L1 cells and adipose tissues from obese rodents 28 and humans. 29 One of the potential mediators of the mevalonate-dependent and insulin-stimulated adipocyte differentiation is the Ras protein, which requires farnesylation for its membrane attachment and biological activity. Whether other prenylated proteins mediate PPARg upregulation or stimulate differentiation independent of PPARg signaling remains elusive. Binding of insulin with its receptor activates PI3K and PKB/Akt, which have a pro-adipogenic role in adipocytes. 30 In contrast, inhibition of PI3K with wortmannin and LY294002 blocks the adipocyte differentiation in 3T3-L1 cells. 30, 31 Additionally, PKB/Akt-knockout mice have impaired development of adipose tissue. 32 PI3K-PKB/Akt pathway also mediates insulin-induced glucose uptake by adipocytes. 33 In the basal state, only 10% of GLUT4 is present at the plasma membrane, 34 whereas more than 90% of GLUT4 is sequestered in the intracellular compartments and is located in ''GLUT4 storage vesicle'', which are the main target of insulin-induced GLUT4 translocation. 35 The activation of PI3K is essential for the activation of Rac1, a Rho family of small G proteins involved in the remodeling of actin that is required for GLUT4 translocation. 36 We stipulated that a blend of farnesol and the PI3K inhibitor LY294002 would illustrate the role of insulin signaling in farnesol-mediated differentiation. On the contrary, the inability of farnesol to reverse the inhibitory effect of LY294002 ( Figure 5 ) indicated that the farnesol effect was either independent of PI3K pathway or insufficient to attenuate the strong effect of LY294002. Whether farnesol acts through the insulin signaling pathway warrants further investigation.
It is interesting to note that geranylgeraniol, also a mevalonate-derived isoprenoid, activates PPARg in 3T3-L1 cells 6 and HCT 116 cells, 20 albeit with a slightly lower potency than that of farnesol. Geranylgeraniol can be phosphorylated and converted to GGPP, much like the way farnesol is converted to FPP. 18 A separate study confirmed activation of PPARg by GGPP, 37 again with slightly lower potency than that of FPP. However, geranylgeraniol, but not farnesol, has been shown to enhance the degradation of HMG CoA reductase 38 and hence suppress the production of mevalonate-derived metabolites, an action that might counteract the geranylgeraniol-or GGPP-mediated PPARg activation. Consistent with the observation by Sever et al. 38 in fibroblasts, in our hands farnesol at concentrations up to 75 mmol/L did not affect the expression of HMG CoA reductase mRNA ( Figure 6 ) following a seven-day incubation with 3T3-F442A adipocytes. The lack of negative impact on HMG CoA reductase may have rendered farnesol a stronger inducer of adipocyte differentiation than geranylgeraniol. In human HepG2 hepatoma cells and Caco-2 colon carcinoma cells, troglitazone-induced PPARg activation led to downregulation of SREBP-2 and HMG CoA reductase mRNA and SREBP-2 protein levels. 39 What contributes to the lack of impact of farnesol on HMG CoA reductase despite its PPARg activation, or whether the PPARg-HMG CoA reductase relationship is cell typespecific remains obscure.
It should be noted that the regulation of adipogenesis in established cell lines such as the 3T3-F442A cells used in the present study may be different from those in primary stromal-vascular cells due to diverse exposures to hormone and growth factors. 40 The murine origin of 3T3-F442A cells may also limit the applicability of current findings in humans.
In summary, we propose that farnesol and its metabolite, FPP, serve as mevalonate-derived adipogenic mediators in activating-directly or indirectly via farnesylated Ras-PPARg signaling to induce glucose uptake and adipocyte differentiation. By enhancing the role of PPARg in adipocyte differentiation, farnesol and other PPARg-activating sesquiterpenes 41 found in plant-based diets may prove to be promising insulin sensitizers. The mevalonate pathway may turn out to be a valid target in interventions for obesity, diabetes, and glucose homeostasis.
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